ArticleCureus2025
Real-World Outcomes of Ribociclib Treatment in Patients With Metastatic Breast Cancer at a Tertiary Care Hospital.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Ribociclib is an important treatment option in patients with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced/metastatic breast cancer (ABC/MBC); however, there are limited data on its efficacy and safety in the South Asian population. This study aims to evaluate outcomes of breast cancer patients treated with ribociclib therapy in terms of progression-free survival (PFS), overall survival (OS), overall response rate (ORR), duration of response (DOR), and assessment of frequency and severity of toxicity at a tertiary care setup in a resource-limited setting. Methodology This was a single-center, retrospective observational study. Patients aged 18 years and older, diagnosed with HR+ HER2- ABC/MBC, registered between January 2016 and December 2021, and treated with ribociclib therapy were included in this study. Results Median PFS for the overall cohort (n = 50) was 14.7 months, with 10 (20%) patients having no progression on last follow-up. Median OS was 30.8 months, and 19 (38%) patients were alive at the time of last follow-up. Median PFS and OS were significantly longer in patients with non-visceral metastatic disease than with extracranial visceral and brain metastatic disease. The ORR was 48%, whereas the clinical benefit rate was 76%, and the median DOR was 18.9 months. Eleven patients achieved a complete response during the course of their treatment. The most common adverse effect was neutropenia (68%), which was manageable with appropriate dose reductions. Conclusion Our retrospective data support the notion that ribociclib-based therapy is effective and safe in patients with HR+/HER2- ABC/MBC; however, as it is a retrospective study with a small sample size, further prospective studies are necessary to further prove these results in the local population, and efforts should be taken in society at large to make this treatment available to all patients who require this treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.